Singapore Diagnostics Maker Fails to Establish SOPs for Investigations

The GMP Letter
A A
Failure to establish standard operating procedures for investigations landed Singapore-based diagnostics maker MP Biomedicals Asia Pacific in hot water with the FDA following a Dec. 10-12, 2018 inspection of its Singapore facility.

To View This Article:

Login

Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $157.00